Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5700147 | Clinical Oncology | 2010 | 5 Pages |
Abstract
This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S.G. Coulson, V.S. Kumar, I.M. Manifold, M.Q. Hatton, S. Ramakrishnan, K.S. Dunn, O.P. Purohit, C. Bridgewater, R.E. Coleman,